• Venetoclax 1257044-40-8

    Venetoclax 1257044-40-8

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Venetoclax 1257044-40-8 CLL Abbvie Jun.27,2031
  • Velpatasvir(PVP)

    Velpatasvir(PVP)

    API’s Name Indication Specification US DMF  EU DMF  CEP
    Velpatasvir(PVP) HCV In-House    
  • Thalidomide

    Thalidomide

    API’s Name Indication Specification US DMF  EU DMF  CEP
    Thalidomide Oncology drug USP/EP      
  • Ticagrelor

    Ticagrelor

    API’s Name Indication Specification US DMF  EU DMF  CEP
    Ticagrelor Anticoagulant In-House 28984  
  • Tofacitnib Citrate

    Tofacitnib Citrate

    API’s Name Indication Specification US DMF  EU DMF  CEP
    Tofacitnib Citrate Rheumatoid arthritis In-House      
  • Sugammadex Sodium

    Sugammadex Sodium

    API’s Name Indication Specification US DMF  EU DMF  CEP
    Sugammadex Sodium Neuromuscular blockade In-House      
  • Sacubitril Hemicalcium

    Sacubitril Hemicalcium

    API’s Name Indication Specification US DMF  EU DMF  CEP
    Sacubitril Hemicalcium   In-House      
  • Sofosbuvir

    Sofosbuvir

    API’s Name Indication Specification US DMF  EU DMF  CEP
    Sofosbuvir HCV In-House 32048  
  • Ribociclib 1374639-75-4

    Ribociclib 1374639-75-4

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Ribociclib 1374639-75-4 HR-positive, HER2-negative Andvance ormetastaticbreast Cancers Novartis
    Pharmaceuticals
    Jun.27, 2028
  • Rivaroxaban

    Rivaroxaban

    API’s Name Indication Specification US DMF  EU DMF  CEP
    Rivaroxaban Anticoagulant In-House TDP    
  • Rosuvastatin Calcium

    Rosuvastatin Calcium

    API’s Name Indication Specification US DMF  EU DMF  CEP
    Rosuvastatin Calcium Hypercholesterolemia In-House/CEP 20705 CEP2015-240
  • Pitavastatin Calcium

    Pitavastatin Calcium

    API’s Name Indication Specification US DMF  EU DMF  CEP
    Pitavastatin Calcium Hypercholesterolemia In-House      
123 Next > >> Page 1 / 3